Confirm with your pharmacist whether storage requirements (Wegovy must be refrigerated) allow for this approach
This post is primarily written for healthcare providers , but if any well-informed patients believe they qualify for treatment and were denied, feel free to share this information with your medical provider
Link: Yoshino, J., et al
Serving multiple states from MI to OH, IN, WI, and FL (Florida: non-injectable dosage forms only)
Obesity and visceral adiposity are key drivers of HFpEF development and progression, and this may be even more amplified in women, who represent the majority of people with the disease, and bear a heavier burden of symptoms and physical limitations due to HFpEF said Mikhail Kosiborod, MD, FACC, senior author of the study and a cardiologist at Saint Luke's Mid-America Heart Institute in Kansas City, Missouri